Bezafibrate treatment: a new medical approach for PBC patients?

Primary Biliary Cirrhosis

Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 2,015 · see citing works

Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

Smit, J., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van ROON, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,443 · see citing works

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648 · see citing works

IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?

Poupon, R. Y., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 534 · see citing works

Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis

Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497 · see citing works

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · see citing works

Natural history of early primary biliary cirrhosis

Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421 · see citing works

Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial

Leuschner, U., Fischer, H., Kurtz, W., Güldütuna, S., Hübner, K., Hellstern, A., Gatzen, M., & Leuschner, M. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91698-3 · Cited by 352 · see citing works

A Prospective Trial of Colchicine for Primary Biliary Cirrhosis

Kaplan, M. M., Alling, D. W., Zimmerman, H. J., Wolfe, H. J., Sepersky, R. A., Hirsch, G. S., Elta, G. H., Glick, K., & Eagen, K. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152304 · Cited by 313 · see citing works

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial

Parés, A. R., Caballería, L., Rodés, J., Bruguera, M., Rodrigo, L., García-Plaza, A., Berenguer, J., Rodrı́guez-Martı́nez, D., Mercader, J., & Velicia, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80216-0 · Cited by 268 · see citing works

Transplantation for Primary Biliary Cirrhosis: Retrospective Analysis of 400 Patients in A Single Center

Garcia, R. F. L., Garcia, C. E., McMaster, P., & Neuberger, J. (2001) · Hepatology · doi:10.1053/jhep.2001.20894 · Cited by 254 · see citing works

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis

Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209 · see citing works

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results.

Mitchison, H., Palmer, J., Bassendine, M., Watson, A., Record, C., & James, O. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90065-w · Cited by 203 · see citing works

Time course of histological progression in primary biliary cirrhosis

Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D. (1996) · Hepatology · doi:10.1002/hep.510230108 · Cited by 184 · see citing works

Primary biliary cirrhosis

Neuberger, J. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05419-6 · Cited by 180 · see citing works

A Prospective Controlled Trial of Azathioprine in Primary Biliary Cirrhosis

Heathcote, J., Ross, A., & Sherlock, S. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80250-8 · Cited by 160 · see citing works

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial.

Lombard, M., Portmann, B., Neuberger, J., Williams, R., Tygstrup, N., Ranek, L., Ring-Larsen, H., Rodés, J., Navasa, M., Trepo, C., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90422-9 · Cited by 148 · see citing works

Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse

José Chianale, B., Vollrath, V., Wielandt, A. M., Amigo, L., Rigotti, A., Nervi, F. O., González, S., ANDRADE, L., Pizarro, M., & Luigi Accatino, L. (1996) · Biochemical Journal · doi:10.1042/bj3140781 · Cited by 143 · see citing works

Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis

Koga, H., Sakisaka, S., Ohishi, M., Sata, M., & Tanikawa, K. (1997) · Hepatology · doi:10.1002/hep.510250505 · Cited by 134 · see citing works

Evaluation of colchicine therapy in primary biliary cirrhosis

Bodenheimer, H. C., Schaffner, F., & Pezzullo, J. C. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90300-9 · Cited by 133 · see citing works

Sustained Biochemical and Histologic Remission of Primary Biliary Cirrhosis in Response to Medical Treatment

Kaplan, M. M., DeLellis, R. A., & Wolfe, H. J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-9-199705010-00002 · Cited by 132 · see citing works

Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration

Crosignani, A., Podda, M., Battezzati, P. M., Bertolini, E., Zuin, M. G., Watson, D., & Setchell, K. D. R. (1991) · Hepatology · doi:10.1002/hep.1840140609 · Cited by 127 · see citing works

New Concepts in Biliary Cirrhosis

Ludwig, J. (1987) · Seminars in Liver Disease · doi:10.1055/s-2008-1040584 · Cited by 117 · see citing works

A Multicenter Randomized Controlled Dose Study of Ursodeoxycholic Acid for Chronic Hepatitis C

Takano, S., Yoshimi, I. T. O., Yokosuka, O., Ohto, M., Uchiumi, K., Hirota, K., & Omata, M. (1994) · Hepatology · doi:10.1002/hep.1840200303 · Cited by 100 · see citing works

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis

Poupon, R., Huet, P., Poupon, R., Bonnand, A., van Nhieu, J. T., & Zafrani, E. (1996) · Hepatology · doi:10.1002/hep.510240520 · Cited by 91 · see citing works

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis

BATTA, A. K., Salen, G., Arora, R., Shefer, S., Tint, S. G., Abroon, J., Eskreis, D., & Katz, S. (1989) · Hepatology · doi:10.1002/hep.1840100404 · Cited by 88 · see citing works

Use of ursodeoxycholic acid in liver diseases

Kumar, D., & Tandon, R. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02376.x · Cited by 87 · see citing works

The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study*1

Lindor, K. D. (1995) · Hepatology · doi:10.1016/0270-9139(95)90624-x · Cited by 87 · see citing works

Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis

Iwasaki, S. (1999) · Hepatology Research · doi:10.1016/s1386-6346(99)00033-9 · Cited by 80 · see citing works

Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters

Vessby, B. O., Lithell, H., Hellsing, K., Östlund‐Lindqvist, A., Gustafsson, I., Boberg, J., & Ledermann, H. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90011-8 · Cited by 78 · see citing works

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.

Jorgensen, R. A., Dickson, E. R., Hofmann, A. F., Rossi, S. S., & Lindor, K. D. (1995) · Gut · doi:10.1136/gut.36.6.935 · Cited by 77 · see citing works

Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis

Sharma, A., Provenzale, D., McKusick, A., & Kaplan, M. M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90085-x · Cited by 67 · see citing works

The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities

Day, A., Feher, M. D., Chopra, R., & Mayne, P. (1993) · Metabolism · doi:10.1016/0026-0495(93)90056-t · Cited by 61 · see citing works

Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy

Kurihara, T., Maeda, A., Shigemoto, M., Yamashita, K., & Hashimoto, E. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05413.x · Cited by 55 · see citing works

A novel treatment for refractory primary biliary cirrhosis?

Miyaguchi, S., Ebinuma, H., Imaeda, H., Nitta, Y., Watanabe, T., Saito, H., & Ishii, H. (2000) · PubMed · Cited by 48 · see citing works

Living Related-Donor Liver Transplantation from Adult to Adult for Primary Biliary Cirrhosis

Ichida, T., Matsunami, H., Kawasaki, S., Makuuchi, M., Harada, T., Itoh, S., & Asakura, H. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-4-199502150-00006 · Cited by 48 · see citing works

D-penicillamine for primary biliary cirrhosis.

James, O. (1985) · Gut · doi:10.1136/gut.26.2.109 · Cited by 44 · see citing works

THE IMPROVED METHOD OF HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC SEPARATION OF INDIVIDUAL BILE ACIDS: FREE AND GLYCINE-CONJUGATED BILE ACIDS

Okuyama, S., Uemura, D., & Hiratå, Y. (1979) · Chemistry Letters · doi:10.1246/cl.1979.461 · Cited by 36 · see citing works

Effect of bezafibrate in the treatment of primary biliary cirrhosis

Kurihara, T., Furukawa, M., Tsuchiya, M., Akimoto, M., Ishiguro, H., Hashimoto, H., Niimi, A., Maeda, A., Shigemoto, M., & Yamasha, K. (2000) · Current Therapeutic Research · doi:10.1016/s0011-393x(00)88530-6 · Cited by 15 · see citing works

Management of primary biliary cirrhosis resistant to ursodeoxycholic acid therapy

Poupon, R. Y. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80438-9 · Cited by 12 · see citing works

The Canadian Multicenter Double‐blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis

Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology · doi:10.1002/hep.1840190512 · Cited by 2 · see citing works

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · see citing works

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 347 · see citing works

Fibrates and cholestasis

Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317 · see citing works

Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration

Geier, A., Wagner, M., Dietrich, C. G., & Trauner, M. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 313 · see citing works

Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein)

Elferink, R. P. J. O., & Paulusma, C. C. (2006) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0062-9 · Cited by 279 · see citing works

New molecular insights into the mechanisms of cholestasis.

Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 270 · see citing works

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid: Pilot study: fenofibrate with UDCA for primary biliary cirrhosis

Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186 · see citing works

The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus

Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176 · see citing works

Nuclear receptors as therapeutic targets in cholestatic liver diseases

Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146 · see citing works

Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver

Trottier, J., Verreault, M., Grepper, S., Monté, D., Bélanger, J., Kaeding, J., Caron, P., Inaba, T. T., & Barbier, O. (2006) · Hepatology · doi:10.1002/hep.21362 · Cited by 120 · see citing works

Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis

Honda, A., Tanaka, A., Kaneko, T., Komori, A., Abe, M., Inao, M., Namisaki, T., Hashimoto, N., Kawata, K., Takahashi, A., et al. (2019) · Hepatology · doi:10.1002/hep.30552 · Cited by 116 · see citing works

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response

Reig, A., Sesé, P., & Parés, A. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.287 · Cited by 115 · see citing works

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107 · see citing works

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases

Halilbasic, E., Baghdasaryan, A., & Trauner, M. A. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.001 · Cited by 98 · see citing works

Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity

Zollner, G., Wagner, M., & Trauner, M. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 89 · see citing works

American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis

Silveira, M. G., Brunt, E. M., Heathcote, J., Gores, G. J., Lindor, K. D., & Mayo, M. J. (2010) · Hepatology · doi:10.1002/hep.23637 · Cited by 87 · see citing works

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis

Jun, I. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 80 · see citing works

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

Liberopoulos, E. N., Florentin, M., Elisaf, M., Mikhailidis, D. P., & Tsianos, E. V. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010120 · Cited by 74 · see citing works

Novel and emerging therapies for cholestatic liver diseases

Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 74 · see citing works

Safety of fibrates in cholestatic liver diseases

Carrion, A. F., Lindor, K. D., & Levy, C. (2021) · Liver International · doi:10.1111/liv.14871 · Cited by 72 · see citing works

Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid

Hazzan, R., & Tur‐Kaspa, R. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c115b3 · Cited by 63 · see citing works

Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy

Xiao, H., Wang, Q., Liu, Y., Zheng Rui, Y. O. U., Zhao Lian, B. I. A. N., Qiu, D., & Ma, X. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2012.00574.x · Cited by 63 · see citing works

Clinical application of transcriptional activators of bile salt transporters

Baghdasaryan, A., Chiba, P., & Trauner, M. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 56 · see citing works

Pharmacological interventions for primary biliary cholangitis

Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 54 · see citing works

Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis

Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50 · see citing works

Treatment of autoimmune liver disease: current and future therapeutic options

Trivedi, P. J., & Hirschfield, G. M. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313478646 · Cited by 49 · see citing works

The Coexistence of Sjögren's Syndrome and Primary Biliary Cirrhosis: A Comprehensive Review

Sun, Y. H., Zhang, W., Li, B., Zou, Z., Selmi, C. F., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8471-1 · Cited by 46 · see citing works

A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis

Hegade, V. S., Bolier, R., Elferink, R. P. J. O., Beuers, U. H., Kendrick, S. F. W., & Jones, D. E. (2015) · Frontline Gastroenterology · doi:10.1136/flgastro-2015-100618 · Cited by 46 · see citing works

Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis

Wagner, M., & Trauner, M. A. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32071-x · Cited by 46 · see citing works

Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA

Tanaka, A., Hirohara, J., Nakanuma, Y., Tsubouchi, H., & Takikawa, H. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0998-z · Cited by 44 · see citing works

Comment on biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis†

Walker, L. J., Newton, J. L., Jones, D. E. J., & Bassendine, M. F. (2008) · Hepatology · doi:10.1002/hep.22670 · Cited by 43 · see citing works

Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis

Reshetnyak, V. I., & Maev, I. V. (2022) · Biomedicines · doi:10.3390/biomedicines10123046 · Cited by 39 · see citing works

Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come

Ghonem, N. S., & Boyer, J. L. (2012) · Hepatology · doi:10.1002/hep.26155 · Cited by 38 · see citing works

New Therapies for Primary Biliary Cirrhosis

Floreani, A., Franceschet, I., Perini, L., Cazzagon, N., Gershwin, M. E., & Bowlus, C. L. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8456-5 · Cited by 37 · see citing works

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis

Guo, C., Yin, Q., Li, J., Zheng, Y., Chen, K., Lu, J., Wang, J., Lu, W., Li, S., Liu, T., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s92041 · Cited by 35 · see citing works

Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up

Sorda, J. A., Ballerga, E. G., Barreyro, F. J., Avagnina, A., Carballo, P., de Lima, A. P., & Daruich, J. R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16618 · Cited by 34 · see citing works

Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review

Smith, H. T., de Souza, A. R., Thompson, A. H., McLaughlin, M., Dever, J. J., Myers, J. A., & Chen, J. V. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07862-z · Cited by 31 · see citing works

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

Bolier, R., de Vries, E. S., Parés, A. R., Helder, J., Kemper, E. M., Zwinderman, K. H., Elferink, R. P. J. O., & Beuers, U. H. (2017) · Trials · doi:10.1186/s13063-017-1966-8 · Cited by 32 · see citing works

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress

Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 30 · see citing works

Natural history and management of primary biliary cirrhosis

Kumagi, T., & Al‐Harthy, N. (2012) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s25998 · Cited by 30 · see citing works

Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis

Akbar, S. M. F., Furukawa, S., Nakanishi, S., Abe, M., Horiike, N., & Onji, M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-004-1518-3 · Cited by 29 · see citing works

Options for Treatment of Primary Biliary Cirrhosis

Oo, Y. H., & Neuberger, J. (2004) · Drugs · doi:10.2165/00003495-200464200-00001 · Cited by 28 · see citing works

Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis

Shen, N., Pan, J., Miao, H., Zhang, H., Xing, L., & Yu, X. F. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1304 · Cited by 28 · see citing works

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar, R., Wong, K. A., Liu, C. H., & Bowlus, C. L. (2018) · Europe PMC (PubMed Central) · Cited by 28 · see citing works

Bezafibrate for primary biliary cirrhosis

Rudić, J. S., Poropat, G., Krstic, M. N., Bjelaković, G., & Gluud, C. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009145.pub2 · Cited by 27 · see citing works

Network Meta-Analysis of Randomized Controlled Trials

Zhu, G., Shi, K., Huang, S., Huang, G., Lin, Y.-Q., Zhou, Z., Braddock, M., Chen, Y., & Zheng, M. (2015) · Medicine · doi:10.1097/md.0000000000000609 · Cited by 27 · see citing works

Long‐term fibrate treatment for PBC

Nakamuta, M., Enjoji, M., Kotoh, K., Shimohashi, N., & Tanabe, Y. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-004-1583-7 · Cited by 26 · see citing works

Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis

Lin, W., Wang, J.-X., & Liu, Y.-J. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02460-0 · Cited by 26 · see citing works

Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta‐analysis

Zhang, Y., Chen, K., Dai, W., Xia, Y., Wang, F., Shen, M., Cheng, P., Wang, C., Yang, J., Zhu, R., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12373 · Cited by 26 · see citing works

Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Rust, C., & Beuers, U. H. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:135 · Cited by 26 · see citing works

Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential

Verreault, M., Kaeding, J., Caron, P., Trottier, J., Grosse, L., Houssin, É., Pâquet, S., Perreault, M., & Barbier, O. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903219220 · Cited by 24 · see citing works

Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.

Dohmen, K., Tanaka, H., & Haruno, M. (2013) · PubMed · doi:10.15017/1398604 · Cited by 24 · see citing works

Effects of Three Different Fibrates on Intrahepatic Cholestasis Experimentally Induced in Rats

El‐Sisi, A. E., Hegazy, S. K., & El‐Khateeb, E. (2013) · PPAR Research · doi:10.1155/2013/781348 · Cited by 24 · see citing works

Targeting the ABCB4 gene to control cholesterol homeostasis

Elferink, R. P. J. O., & Beuers, U. H. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.607163 · Cited by 22 · see citing works

Primary biliary cirrhosis: Report of a focus study group

Bergasa, N. V., Mason, A. L., Floreani, A., Heathcote, J., Swain, M. G., Jones, D. E. J., Lindor, K., Bassendine, M. F., & Worman, H. J. (2004) · Hepatology · doi:10.1002/hep.1840400434 · Cited by 23 · see citing works

Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Khakoo, N. S., Sultan, S., Reynolds, J. M., & Levy, C. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07704-4 · Cited by 22 · see citing works

Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life

Sivakumar, T., & Kowdley, K. V. (2021) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s256692 · Cited by 19 · see citing works

The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression

Enjoji, M., Yada, R., Fujino, T., Yoshimoto, T., Yada, M., Harada, N., Higuchi, N., Kato, M., Kohjima, M., Taketomi, A., et al. (2009) · Hepatology International · doi:10.1007/s12072-009-9137-y · Cited by 19 · see citing works

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis

Wang, C., Shi, Y., Wang, X., Ma, H., Liu, Q., Gao, Y., & Niu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940688 · Cited by 19 · see citing works

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis

Dohmen, K., Onohara, S.-Y., & Harada, S. (2021) · The Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.092 · Cited by 18 · see citing works

Bezafibrate for primary biliary cirrhosis

Rudić, J. S., Poropat, G., Krstic, M. N., Bjelaković, G., & Gluud, C. N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009145 · Cited by 17 · see citing works

Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis

Xu, C., Yue, R., Lv, X., Wang, S., & Du, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835991 · Cited by 16 · see citing works

The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis

Kawata, K., Joshita, S., Shimoda, S., Yamashita, Y., Yamashita, M., Kitsugi, K., Takatori, S., Ohta, K., Ito, J., Shimoyama, S., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13584 · Cited by 16 · see citing works

Pathophysiological analysis of primary biliary cirrhosis focusing on choline/phospholipid metabolism

Kohjima, M., Enjoji, M., Yada, R., Yoshimoto, T., Nakamura, T., Fukuizumi, K., Fukushima, N., Murata, Y., Nakashima, M., Kato, M., et al. (2014) · Liver International · doi:10.1111/liv.12526 · Cited by 16 · see citing works

Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review

Kanda, T., Sasaki, R., Kimura, N., Abé, H., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., Tsuchiya, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051883 · Cited by 14 · see citing works

Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials

Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F. O., & Pourfaraji, S. M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03821-2 · Cited by 14 · see citing works

Hepatobiliary membrane transporters in primary biliary cirrhosis

Takeyama, Y., & Sakisaka, S. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00912.x · Cited by 14 · see citing works

Review article: nuclear receptors and liver disease – current understanding and new therapeutic implications

Elfaki, D., Bjornsson, E. S., & Lindor, K. D. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04104.x · Cited by 14 · see citing works

Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy

Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 14 · see citing works

Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis

Zhang, H., Li, S., Feng, Y.-H., Zhang, Q., & Xie, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00904-2 · Cited by 14 · see citing works

Current and promising therapy for primary biliary cholangitis

Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 15 · see citing works

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials

Agrawal, R. (2019) · Annals of Gastroenterology · doi:10.20524/aog.2019.0403 · Cited by 14 · see citing works

Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis

Zhu, G., Huang, S., Huang, G., Wang, L., Lin, Y.-Q., Wu, Y.-M., Shi, K., Wang, J., Zhou, Z., Braddock, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4528 · Cited by 12 · see citing works

Proposed therapies in primary biliary cholangitis

Floreani, A., Sun, Y. H., Zou, Z. S., Li, B., Cazzagon, N., Bowlus, C. L., & Gershwin, M. E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1121810 · Cited by 12 · see citing works

The Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome

Hussain, N., & Trivedi, P. J. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.007 · Cited by 14 · see citing works

Nuclear receptor ligands in therapy of cholestatic liver disease

Sturm, E. (2009) · Frontiers in bioscience · doi:10.2741/3529 · Cited by 12 · see citing works

New therapeutics in primary biliary cirrhosis: will there ever be light?

Invernizzi, P., & Gershwin, M. E. (2014) · Liver International · doi:10.1111/liv.12354 · Cited by 11 · see citing works

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis

Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24391 · Cited by 11 · see citing works

Current Treatment Options for Primary Biliary Cholangitis

Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. L. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.003 · Cited by 11 · see citing works

The treatment of primary biliary cholangitis: from shadow to light

Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 10 · see citing works

Novel Therapies on Primary Biliary Cirrhosis

Czul, F., & Levy, C. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.006 · Cited by 10 · see citing works

Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness

Jopson, L., Khanna, A., Peterson, P., Rudell, E., Corrigan, M., & Jones, D. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5074-8 · Cited by 9 · see citing works

Treatment of Primary Biliary Cholangitis

Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9 · see citing works

Comparative effectiveness of peroxisome proliferator–activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis

Martins, A., Khakoo, N. S., Reddy, A., Reynolds, J. M., Corpechot, C., Rousseau, A., Murad, M., Sultan, S., & Levy, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001465 · Cited by 9 · see citing works

Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?

Parés, A. R. (2014) · Clinical Liver Disease · doi:10.1002/cld.311 · Cited by 9 · see citing works

Therapeutic advances for primary biliary cholangitis: the old and the new

Wang, L., Zhang, F., & Zhang, X. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000591 · Cited by 8 · see citing works

Primary Biliary Cirrhosis

Silveira, M. G. (2014) · Clinical gastroenterology · doi:10.1007/978-1-4939-1013-7_3 · Cited by 9 · see citing works

Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis

Jiang, Z., Liu, X., Yuan, Z., He, H., Wang, J., Zhang, X., Gong, Z. L., Hou, L., Shen, L., Guo, F., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00189 · Cited by 8 · see citing works

Investigational drugs in early phase development for primary biliary cholangitis

Gochanour, E. M., & Kowdley, K. V. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1857364 · Cited by 8 · see citing works

No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!

Halliday, J., & Chapman, R. W. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06837.x · Cited by 7 · see citing works

Safety considerations for the management of cholestatic itch

Trivella, J. P., & Levy, C. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1915984 · Cited by 6 · see citing works

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Schattenberg, J. M., Bañales, J. M., Hirschfield, G. M., Trivedi, P., Cable, E. E., McWherter, C. A., Billin, A. N., Crittenden, D. B., & Budas, G. R. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70598 · Cited by 5 · see citing works

Fibrates and Fibrate-induced Liver Injury in Primary Biliary Cholangitis

Vanasco, A., & vanSonnenberg, E. (2023) · Gene Expression · doi:10.14218/ge.2023.00015 · Cited by 5 · see citing works

Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis

Fejfar, T., Vaňásek, T., & Hůlek, P. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.084 · Cited by 5 · see citing works

Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman

Kanda, T. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i17.2607 · Cited by 5 · see citing works

Primary Biliary Cirrhosis

Clark, V., & Levy, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_3 · Cited by 5 · see citing works

Meta‐Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis

Martins, A., Khakoo, N. S., Corpechot, C., Rousseau, A., Reynolds, J. M., Kremer, A. E., Murad, M. H., Sultan, S., & Levy, C. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70634 · Cited by 4 · see citing works

Peroxisome Proliferator‐Activated Receptor ( PPAR ) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid ( UDCA ): A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Zaidi, M. H., Haider, Z., Sadia, F., Tayyab, M., Tariq, M., Ans, H., Javaid, M. B., Khan, A., Ahmad, M. H., Rasheed, R., et al. (2025) · JGH Open · doi:10.1002/jgh3.70196 · Cited by 4 · see citing works

Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases

Haga, Y., Kanda, T., Sasaki, R., Nakamura, M., Takahashi, K., Wu, S., Yasui, S., Arai, M., Nakamoto, S., & Yokosuka, O. (2016) · Diseases · doi:10.3390/diseases4040038 · Cited by 4 · see citing works

Primary biliary cholangitis: assessment and management strategies

Abbas, S. N., Jones, D. E., Kallis, Y. N., Maher, L., & Patanwala, I. (2021) · Gastrointestinal Nursing · doi:10.12968/gasn.2021.19.sup4.s1 · Cited by 3 · see citing works

Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid

Hazzan, R., & Tur‐Kaspa, R. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c115b3 · Cited by 63 · see citing works

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107 · see citing works

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis

Jun, I. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 80 · see citing works

Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid

Takeuchi, Y., Ikeda, F., Fujioka, S., Takaki, T., Osawa, T., Yasunaka, T., Miyake, Y., Takaki, A., Iwasaki, Y., Kobashi, H., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06737.x · Cited by 41 · see citing works

Effect of bezafibrate in the treatment of primary biliary cirrhosis

Kurihara, T., Furukawa, M., Tsuchiya, M., Akimoto, M., Ishiguro, H., Hashimoto, H., Niimi, A., Maeda, A., Shigemoto, M., & Yamasha, K. (2000) · Current Therapeutic Research · doi:10.1016/s0011-393x(00)88530-6 · Cited by 15 · see citing works